Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Reports on Cryoport

Sort by

Cryoport: This Unique Company is Poised for Explosive Sales Growth; Price Weakness is a Buying Opportunity (CYRX, Buy, $6.68)

Monday, November 6, 2017 · 9:26 am

Read More

Cryoport: As Its Clients Transition from Clinical Development to Commercial, Growth Could Be Explosive (CYRX, $6.89, Buy)

Thursday, August 10, 2017 · 11:48 am

Read More

Cryoport: Upping 2020 Price Target from $14.50 to $20.00 (CYRX, Buy, $6.89)

Wednesday, July 26, 2017 · 8:26 am

Read More

My Approach to Investing in CAR-T Drug Development: Cryoport (CYRX, Buy, $5.67)); Kite (KITE, Neutral, $104.34); Juno (JUNO, Neutral, $27.87), Novartis, (NVS, No opinion, $84.85)

Wednesday, July 19, 2017 · 9:40 am

Read More

Cryoport: Thoughts About FDA AdCom Meeting on Novartisís CAR-T Drug Tisagenlecleucel (CYRX, Buy, $4.86)

Tuesday, July 11, 2017 · 5:40 pm

Read More

Cryoport: Observations on 1Q, 2017 Results (CYRX, Buy, $3.05)

Thursday, May 11, 2017 · 4:00 pm

Read More

Thoughts on the Probable Launches of the First CAR-T Drugs; Cryoport is a Novel Way to Invest In This: Cryoport (CYRX, Buy, $2.36) and Kite (KITE, Neutral, $83.37)

Thursday, April 27, 2017 · 8:39 am

Read More

Cryoport: Initiating Coverage of this Highly Unique Health Care Company with a Buy (CYRX, Buy, $2.25)

Wednesday, April 12, 2017 · 11:07 am

Read More

There are 8 reports on file.

« Back to Company Reports Index